208 related articles for article (PubMed ID: 25458054)
1. Biomarker validation and testing.
Hayes DF
Mol Oncol; 2015 May; 9(5):960-6. PubMed ID: 25458054
[TBL] [Abstract][Full Text] [Related]
2. Considerations for Implementation of Cancer Molecular Diagnostics Into Clinical Care.
Hayes DF
Am Soc Clin Oncol Educ Book; 2016; 35():292-6. PubMed ID: 27249708
[TBL] [Abstract][Full Text] [Related]
3. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
4. Biomarker development in the context of urologic cancers.
Kelloff GJ; Sigman CC; Scher HI
Urol Oncol; 2015 Jun; 33(6):295-301. PubMed ID: 25746942
[TBL] [Abstract][Full Text] [Related]
5. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226
[TBL] [Abstract][Full Text] [Related]
6. Cancer biomarkers.
Henry NL; Hayes DF
Mol Oncol; 2012 Apr; 6(2):140-6. PubMed ID: 22356776
[TBL] [Abstract][Full Text] [Related]
7. (Very) Early technology assessment and translation of predictive biomarkers in breast cancer.
Miquel-Cases A; Schouten PC; Steuten LM; Retèl VP; Linn SC; van Harten WH
Cancer Treat Rev; 2017 Jan; 52():117-127. PubMed ID: 27992844
[TBL] [Abstract][Full Text] [Related]
8. Status of Immune Oncology: Challenges and Opportunities.
Cesano A; Marincola FM; Thurin M
Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
[TBL] [Abstract][Full Text] [Related]
9. Current concepts of tumor markers in bladder cancer.
Droller MJ
Urol Clin North Am; 2002 Feb; 29(1):229-34. PubMed ID: 12109349
[TBL] [Abstract][Full Text] [Related]
10. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint.
Hayes DF
J Clin Oncol; 2021 Jan; 39(3):238-248. PubMed ID: 33326253
[TBL] [Abstract][Full Text] [Related]
11. Validation of new cancer biomarkers: a position statement from the European group on tumor markers.
Duffy MJ; Sturgeon CM; Sölétormos G; Barak V; Molina R; Hayes DF; Diamandis EP; Bossuyt PM
Clin Chem; 2015 Jun; 61(6):809-20. PubMed ID: 25882892
[TBL] [Abstract][Full Text] [Related]
12. Pragmatic issues in biomarker evaluation for targeted therapies in cancer.
de Gramont A; Watson S; Ellis LM; Rodón J; Tabernero J; de Gramont A; Hamilton SR
Nat Rev Clin Oncol; 2015 Apr; 12(4):197-212. PubMed ID: 25421275
[TBL] [Abstract][Full Text] [Related]
13. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
Hayes DF; Bast RC; Desch CE; Fritsche H; Kemeny NE; Jessup JM; Locker GY; Macdonald JS; Mennel RG; Norton L; Ravdin P; Taube S; Winn RJ
J Natl Cancer Inst; 1996 Oct; 88(20):1456-66. PubMed ID: 8841020
[TBL] [Abstract][Full Text] [Related]
14. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers in prostate cancer management. Is there something new?
Carrion DM; Gómez Rivas J; Álvarez-Maestro M; Martínez-Piñeiro L
Arch Esp Urol; 2019 Mar; 72(2):105-115. PubMed ID: 30855011
[TBL] [Abstract][Full Text] [Related]
16. Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives.
Mordente A; Meucci E; Martorana GE; Silvestrini A
Adv Exp Med Biol; 2015; 867():9-26. PubMed ID: 26530357
[TBL] [Abstract][Full Text] [Related]
17. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST).
Barker PE
Ann N Y Acad Sci; 2003 Mar; 983():142-50. PubMed ID: 12724219
[TBL] [Abstract][Full Text] [Related]
18. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
19. Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
VanderLaan PA; Rangachari D; Majid A; Parikh MS; Gangadharan SP; Kent MS; McDonald DC; Huberman MS; Kobayashi SS; Costa DB
Lung Cancer; 2018 Feb; 116():90-95. PubMed ID: 29413057
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
